Drugs / Veverimer
Veverimer
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07473713 | Apr 2026 → Mar 2028 expected | — | Tufts Medical Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02809183 | Mar → Nov 2016 | metabolic acidosis | Tricida, Inc. | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT07355062 | Jan 2026 → Jun 2027 expected | chronic kidney disease, metabolic acidosis | Renibus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03710291 | Nov 2018 → Aug 2022 | chronic kidney disease, metabolic acidosis | Tricida, Inc. | Terminated | Missed primary |
| Phase 3 | NCT03390842 | Dec 2017 → Feb 2019 | metabolic acidosis | Tricida, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03317444 | Sep 2017 → May 2018 | metabolic acidosis | Tricida, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-10 | Renibus Therapeutics, Inc. | Regulatory Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM) renibus.com ↗
Renibus Therapeutics® (“Renibus”), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-10 | Renibus Therapeutics, Inc. | Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM) renibus.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Veverimer | “Veverimer” NCT03390842 ↗ |
| Known as | TRC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03710291 ↗ |
| Known as | Veverimere | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298196 ↗ |
| Known as | Veverimero | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298196 ↗ |
| Modality | Other / unclassified | “Veverimer, a non-absorbed, counterion-free, polymeric drug candidate selectively binds and removes hydrochloric acid from the gastrointestinal lumen.” PMID 31248662 ↗ Jun 2019 |
| Route | Oral | “oral suspension” NCT02809183 ↗ |